ABBVIE-M22-947
Phase I
OPEN TO ACCRUAL
A Dose Escalation and Expansion Study of AbbVie's Compound in Combination with Anti-Cancer Myeloma Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
ARCELLX-ACLX-001-DDBCMA
Phase I
OPEN TO ACCRUAL
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma, Including Long-Term Safety Follow-Up
BEIGENE-BGB-11417-105
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination with Dexamethasone and Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and t(11;14)
CARSGEN-CT053-MM-02
Phase I/II
OPEN TO ACCRUAL
Open Label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR-BCMA T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma
CELGENE-CC-92328-MM-001
Phase I
OPEN TO ACCRUAL
A Phase 1, Multi-Center, Open-Label, Dose Finding Study of CC-92328 in Subjects with Relapsed and/or Refractory Multiple Myeloma
COMPUGEN-CPG-02-101
Phase I
OPEN TO ACCRUAL
A Phase 1 Study of the Safety and Tolerability of COM902 in Subjects with Advanced Malignancies
FATE-FT576-101-MM
Phase I
OPEN TO ACCRUAL
A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
ICHNOS-ISB-1442-101
Phase I/II
OPEN TO ACCRUAL
A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma
IIT-CHHABRA-EMBRACE-MM
Phase II
OPEN TO ACCRUAL
A Multicenter Phase II Study of Maintenance Belantamab Mafodotin (Blenrep®) after BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
IIT-DHAKAL-IMPEDE-SGZ-12356
Phase II
OPEN TO ACCRUAL
A Multisite, Phase II Study of Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
NOVARTIS-ADPT07A12101BCMA-CART
Phase I
OPEN TO ACCRUAL
Phase I, Open Label Study of B-Cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients with Relapsed and/or Refractory Multiple Myeloma